
Early Diagnosis Of Cancer Saves Human Lives
Light-Hope Dx is a US-based multinational company that develops PCR-based test for early cancer detection using liquid biopsy
Light-Hope Dx is a US-based multinational company that develops PCR-based test for early cancer detection using liquid biopsy
We are dedicated to providing a non-invasive method for an accurate early diagnosis of human cancer affordable to everyone everywhere.
The importance of Early Cancer Diagnosis is underscored by the World Health Organisation as below.
"Early diagnosis of cancer focuses on detecting symptomatic patients as early as possible so they have the best chance for successful treatment. When cancer care is delayed or inaccessible there is a lower chance of survival, greater problems associated with treatment and higher costs of care. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage and is therefore an important public health strategy in all settings."
Light-Hope Diagnostics, Inc. is at the forefront of developing affordable PCR-based IVD products for early diagnosis of human cancer utilizing non-coding RNAs as biomarkers in liquid biopsy.
We are currently performing the analytical/clinical validation of our first PCR-based IVD product for early detection of breast cancer and its subtypes (ER+/-, PR+/-, HER2+/- and triple negative). Mammogram often fails to accurately detect breast cancer in its early stages--especially in young women where it has been on rise with an alarming rate in recent years. Our tests rely on RNA biomarkers, which are a group of genetic markers present in liquid biopsy. The RNA-based early detection of cancer using liquid biopsy is a promising technology that has potential to revolutionize cancer diagnosis and screening, and save countless human lives.
Our forthcoming IVD products for early diagnosis of the following cancer are in the research and development phase.
Our long-term goal is to develop a Multi-cancer Early Detection (MCED) Test which can simultaneously detect at least five major forms of human cancer, namely, breast, ovarian, lung, pancreatic, and prostate.
The financial barrier, caused due to a high cost of currently available cancer diagnostic tests, limits the capacity for early diagnosis of cancer--especially in resource-poor settings. We overcome this barrier by providing an affordable PCR-based test (IVD product) that detects cancer early in symptomatic (early cancer diagnosis) as well as asymptomatic (cancer screening) individuals. Utilizing our 20+ years of experience in enzymology, DNA/RNA biochemistry, and protein science, we have developed a proprietary formulation of PCR reagents and a freeze-drying (lyophilization) method for their long-term stabilization at a higher ambient temperature. This feature virtually eliminates the cold chain requirement for our IVD products (even in tropical countries, e.g., India, Africa) and make them affordable and accessible to everyone everywhere.
We are currently present in the USA and India. Our presence in India is important for the company growth globally with the following objectives.
1. To manufacture our IVD products at low cost.
2. To perform cost-effective clinical trial of our products on Indian population (in collaboration with cancer hospitals in India).
3. To provide affordable methods for early cancer detection to millions of low-income Indian after the regulatory approval of our product by the CDSCO (the Indian FDA).
4. To participate in MAKE IN INDIA initiative of the Government of India(https://www.pmindia.gov.in/en/major_initiatives/make-in-india/), and to secure non-dilutive funding from the Indian federal government, namely, BIRAC; https://www.birac.nic.in/
We are actively looking for investors, collaborators, and advisors both in the USA as well as in India to partner with us. So, please feel free to contact us.
48 Rio Grande Street, Salt Lake City, Utah 84101, United States
Mon | By Appointment | |
Tue | By Appointment | |
Wed | By Appointment | |
Thu | By Appointment | |
Fri | By Appointment | |
Sat | Closed | |
Sun | Closed |
We look forward to potential collaborations with people and organizations interested in working with us.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.